



FORM PTO-1449

 U.S. Dept. of Commerce
 Patent and Trademark Office

Atty Docket No.

P1101R2D1

Serial No.

10/052,798

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

02 Nov 2001

Group

1646

To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ERA	*	1 08/815,255					12.03.97
	*	2 08/829,536					28.03.97
	*	3 08/883,036					26.06.97
	*	4 3,691,016	12.09.72	Patel, R.			
	*	5 3,969,287	13.07.76	Jaworek et al.			
	*	6 4,179,337	18.12.79	Davis et al.			
	*	7 4,195,128	25.03.80	Hildebrand et al.			
	*	8 4,229,537	21.10.80	Hodgins et al.			
	*	9 4,247,642	27.01.81	Hirohara et al.			
	*	10 4,301,144	17.11.81	Iwashita et al.			
	*	11 4,330,440	18.05.82	Ayers et al.			
	*	12 4,342,566	03.08.82	Theofilopoulos et al.			
	*	13 4,399,216	16.08.83	Axel et al.			
	*	14 4,419,446	06.12.83	Howley et al.			
	*	15 4,496,689	29.01.85	Mitra, G.			
	*	16 4,601,978	22.07.86	Karin, M.			
	*	17 4,640,835	03.02.87	Shimizu et al.			
	*	18 4,670,417	02.06.87	Iwasaki et al.			
	*	19 4,676,980	30.06.87	Segal et al.			
	*	20 4,736,866	12.04.88	Leder et al.			
	*	21 4,791,192	13.12.88	Nakagawa et al.			
	*	22 4,816,567	28.03.89	Cabilly et al.			
	*	23 4,870,009	26.09.89	Evans et al.			
	*	24 4,965,199	23.10.90	Capon et al.			
	*	25 5,010,182	23.04.91	Brake et al.			
	*	26 5,364,934	15.11.94	Drayna et al.			
	*	27 6,046,048	04.04.00	Ashkenazi et al.			
	*	28 6,072,047	06.06.00	Rauch et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
ERA	*	29 036,776 A2	30.09.81	EPO				
	*	30 073,657	09.03.83	EPO				
	*	31 117,058 A2	29.08.84	EPO				
	*	32 117,060 A2	29.08.84	EPO				
	*	33 125,023 A1	14.11.84	EPO				

 Examiner *Eileen B. O'Nara* Date Considered *9/23/03*

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

File Copy

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Adams et al.	
				Filing Date 02 Nov 2001	Group 1646 To Be Assigned

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
EP		* 34 173,494	05.03.86	EPO				
		* 35 278,776	17.08.88	EPO				
		* 36 307,247 B1	15.03.89	EPO				
		* 37 321,196	21.06.89	EPO				
		* 38 362,179 A2	04.04.90	EPO				
		* 39 417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
		* 40 510,691	28.10.92	EPO				
		* 41 870,827 A2	14.10.98	EPO				
		* 42 266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)				
		* 43 91/00360		PCT				
		* 44 92/20373		PCT				
		* 45 93/08829		PCT				
		* 46 WO 00/66156	09.11.00	PCT				
		* 47 WO 87/05330	11.09.87	PCT				
		* 48 WO 89/02922	06.04.89	PCT				
		* 49 WO 89/05859	29.06.89	PCT				
		* 50 WO 90/13646	15.11.90	PCT (ENGLISH ABSTRACT ATTACHED)				
		* 51 WO 91/00358	10.01.91	PCT				
		* 52 WO 91/08291	13.06.91	PCT				
		* 53 WO 92/01047	23.01.92	PCT				
		* 54 WO 92/20791	26.11.92	PCT				
		* 55 WO 93/00109	07.01.93	PCT				
		* 56 WO 93/06213	01.04.93	PCT				
		* 57 WO 93/11236	10.06.93	PCT				
		* 58 WO 93/19172	30.09.93	PCT				
		* 59 WO 94/04679	03.03.94	PCT				
		* 60 WO 94/04690	03.03.94	PCT				
		* 61 WO 94/29348	22.12.94	PCT				
		* 62 WO 95/01438	12.01.95	PCT				
		* 63 WO 95/10540	20.04.95	PCT				
		* 64 WO 95/11301	27.04.95	PCT				
		* 65 WO 95/15388	08.06.95	PCT				
		* 66 WO 95/31544	23.11.95	PCT				
		* 67 WO 97/01633	16.01.97	PCT				
		* 68 WO 97/25428	17.07.97	PCT				
		* 69 WO 98/35986	20.08.98	PCT				

Examiner

Eileen B. O'Han

Date Considered

9/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT		Applicant Adams et al.		
(Use several sheets if necessary)		Filing Date 02 Nov 2001	Group 1646 To Be Assigned	


FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
EA		* 70 WO 98/41629	24.09.98	PCT				
		* 71 WO 98/46643	22.10.98	PCT				
		* 72 WO 98/51793	19.11.98	PCT				
		* 73 WO 98/58062	23.12.98	PCT				
		* 74 WO 99/02653	21.01.99	PCT				
		* 75 WO 99/09165	25.02.99	PCT				
		* 76 WO 99/11791	11.03.99	PCT				
		* 77 WO 99/12963	18.03.99	PCT				
		* 78 WO 99/64461	16.12.99	PCT				
		* 79 2,211,504	05.07.89	UNITED KINGDOM				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


EA	* 80	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for μ , α , γ_1 , γ_2 a, and γ_3 chains" <u>Biochemistry</u> 19:2711-2719 (1980)
	* 81	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
	* 82	Aplin and Wriston, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)
	* 83	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995)
	* 84	Ashkenazi et al., "Induction of Apoptosis by APO-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>European Cytokine Network</u> 7:159-(1996)
	* 85	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	* 86	Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium, Dickey et al., University of Texas M.D. Anderson Hospital (1987)
	* 87	Baldwin, A., "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
	* 88	Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" <u>Cell</u> 33:729-740 (July 1983)
	* 89	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	* 90	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
	* 91	Bianchi et al., "Transformation of the yeast Kluyveromyces lactis by New Vectors Derived from the 1.6 μ m Circular Plasmid pKD1" <u>Curr. Genet.</u> 12:185-192 (1987)
	* 92	"BLAST Results A-1 - A-47" (GenBank)

Examiner	<i>Elain B. O'Han</i>	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
			Applicant Adams et al.	
			Filing Date 02 Nov 2001	Group 1646 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
EA	* 93	"BLAST Results B-1 - B-31" (GenBank, -EST)		
	* 94	"BLAST Results C-1 - C-36" (Patent)		
	* 95	"BLAST Results D-1 - D-40" (Dayhoff -patent)		
	* 96	"BLAST Results E-1 - E-25" (Human -pat)		
	* 97	"BLAST Results F-1 - F-52" (Dayhoff)		
	* 98	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)		
	* 99	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)		
	*100	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)		
	*101	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)		
	*102	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)		
	*103	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)		
	*104	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by Monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)		
	*105	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)		
	*106	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)		
	*107	Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" <u>Year in Immunology</u> 7:33-40 (1993)		
	*108	Byrn et al., "Biological Properties of a CD4 Immunoadhesin" <u>Nature</u> 344:667-670 (April 12, 1990)		
	*109	Canaani et al., "Regulated Expression of Human Interferon β_1 Gene After Transduction into Cultured Mouse and Rabbit Cells" <u>Proc. Natl. Acad. Sci. USA</u> 79:5166-5170 (September 1982)		
	*110	Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <u>Nature</u> 337:525-531 (1989)		
	*111	Caron et al., "Engineered humanized dimeric forms of IgG are more effective antibodies" <u>Journal of Experimental Medicine</u> 176(4):1191-1195 (1992)		
	*112	Carter et al., "Antibody Engineering Using Very Long Template-Assembled Oligonucleotides" <u>Methods: A Companion to Methods in Enzymology</u> 3(3):183-192 (Dec 1991)		
Examiner <i>Celia B. O'Hare</i>			Date Considered 9/23/03	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798																																																																																																				
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Adams et al.																																																																																																						
		Filing Date 02 Nov 2001	Group 1646 To Be Assigned																																																																																																					
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)																																																																																																								
<p><i>EPA</i></p> <table border="0"> <tr> <td>*113</td> <td colspan="4">Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)</td> </tr> <tr> <td>*114</td> <td colspan="4">Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1985)</td> </tr> <tr> <td>*115</td> <td colspan="4">Cha et al., "Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity" <u>The Journal of Biological Chemistry, JBC Papers in Press</u> Vol. 275(40):31171-31177 (July 11, 2000)</td> </tr> <tr> <td>*116</td> <td colspan="4">Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)</td> </tr> <tr> <td>*117</td> <td colspan="4">Chang et al., "Phenotypic Expression in <i>E. coli</i> of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)</td> </tr> <tr> <td>*118</td> <td colspan="4">Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-κB Pathway" <u>Immunity</u> 7:821-830 (1997)</td> </tr> <tr> <td>*119</td> <td colspan="4">Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)</td> </tr> <tr> <td>*120</td> <td colspan="4">Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)</td> </tr> <tr> <td>*121</td> <td colspan="4">Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)</td> </tr> <tr> <td>*122</td> <td colspan="4">Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)</td> </tr> <tr> <td>*123</td> <td colspan="4">Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)</td> </tr> <tr> <td>*124</td> <td colspan="4">Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)</td> </tr> <tr> <td>*125</td> <td colspan="4">Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)</td> </tr> <tr> <td>*126</td> <td colspan="4">Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)</td> </tr> <tr> <td>*127</td> <td colspan="4">Chuntharapai et al., "The induction and blocking of apoptosis by anti Apo2 monoclonal antibodies" <u>FASEB Journal</u> (Annual Meeting of the Professional Research Scientists for Experimental Biology) 13(4):A518 (1999)</td> </tr> <tr> <td>*128</td> <td colspan="4">Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)</td> </tr> <tr> <td>*129</td> <td colspan="4">Cohen, "Programmed Cell Death in the Immune System" <u>Advances in Immunol.</u> 50:55-85 (1991)</td> </tr> <tr> <td>*130</td> <td colspan="4">Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u>, New York:Alan R. Liss, Inc. pps. 77-96 (1985)</td> </tr> <tr> <td>*131</td> <td colspan="4">Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u>, San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)</td> </tr> <tr> <td>✓</td> <td colspan="4">Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" <u>Methods in Cell Biol.</u> 41:15-38 (1994)</td> </tr> </table>					*113	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)				*114	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1985)				*115	Cha et al., "Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity" <u>The Journal of Biological Chemistry, JBC Papers in Press</u> Vol. 275(40):31171-31177 (July 11, 2000)				*116	Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)				*117	Chang et al., "Phenotypic Expression in <i>E. coli</i> of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)				*118	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway" <u>Immunity</u> 7:821-830 (1997)				*119	Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)				*120	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)				*121	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)				*122	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)				*123	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)				*124	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)				*125	Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)				*126	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)				*127	Chuntharapai et al., "The induction and blocking of apoptosis by anti Apo2 monoclonal antibodies" <u>FASEB Journal</u> (Annual Meeting of the Professional Research Scientists for Experimental Biology) 13(4):A518 (1999)				*128	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)				*129	Cohen, "Programmed Cell Death in the Immune System" <u>Advances in Immunol.</u> 50:55-85 (1991)				*130	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)				*131	Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)				✓	Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" <u>Methods in Cell Biol.</u> 41:15-38 (1994)			
*113	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)																																																																																																							
*114	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1985)																																																																																																							
*115	Cha et al., "Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity" <u>The Journal of Biological Chemistry, JBC Papers in Press</u> Vol. 275(40):31171-31177 (July 11, 2000)																																																																																																							
*116	Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)																																																																																																							
*117	Chang et al., "Phenotypic Expression in <i>E. coli</i> of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)																																																																																																							
*118	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway" <u>Immunity</u> 7:821-830 (1997)																																																																																																							
*119	Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)																																																																																																							
*120	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)																																																																																																							
*121	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)																																																																																																							
*122	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)																																																																																																							
*123	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)																																																																																																							
*124	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)																																																																																																							
*125	Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)																																																																																																							
*126	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)																																																																																																							
*127	Chuntharapai et al., "The induction and blocking of apoptosis by anti Apo2 monoclonal antibodies" <u>FASEB Journal</u> (Annual Meeting of the Professional Research Scientists for Experimental Biology) 13(4):A518 (1999)																																																																																																							
*128	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)																																																																																																							
*129	Cohen, "Programmed Cell Death in the Immune System" <u>Advances in Immunol.</u> 50:55-85 (1991)																																																																																																							
*130	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)																																																																																																							
*131	Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)																																																																																																							
✓	Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" <u>Methods in Cell Biol.</u> 41:15-38 (1994)																																																																																																							
Examiner <i>Elder B. O'Han</i>		Date Considered 9/23/03																																																																																																						
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																																																																																																								



FORM PTO-1449

 U.S. Dept. of Commerce
 Patent and Trademark Office

 Atty Docket No.
 P1101R2D1

 Serial No.
 10/052,798

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

 Applicant
 Adams et al.


 Filing Date
 02 Nov 2001

 Group 1646
 To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

EWA	David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase." <u>Biochemistry</u> 13(5):1014-1021 (1974)	
	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)	
	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)	
	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)	
	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Mol. Appl. Gen.</u> 1:561-573 (1982)	
	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press pps. 1-16;133-142 (1995)	
	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas" <u>Proc. Natl. Acad. Sci. USA</u> 77(10):6027-6031 (1980)	
	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" <u>Journal of Biological Chemistry</u> 257:3105-3109 (1982)	
	Eck and Sprang, "The structure of tumor necrosis factor- α at 2.6 Å resolution" <u>Journal of Biological Chemistry</u> 264(29):17595-17605 (1989)	
	Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor- β) at 1.9-Å Resolution" <u>J. Bio. Chem.</u> 267:2119-2122 (1992)	
	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)	
	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)	
	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)	
	Fadok et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages" <u>J. Immunol.</u> 148:2207-2216 (1992)	
	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)	
	Field et al., "Purification of a RAS-Responsive Adenyllyl Cyclase Complex from <u>Saccharomyces cerevisiae</u> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)	
	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" <u>Nature</u> 273:113-120 (May 11, 1978)	
	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by <u>Kluyveromyces</u> Yeasts" <u>Bio/Technology</u> 9:968-975 (1991)	
	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)	
	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)	
✓	Examiner: <u>Eileen B. O'Hara</u>	Date Considered 9/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

 U.S. Dept. of Commerce
 Patent and Trademark Office

Atty Docket No.

P1101R2D1

Serial No.

10/052,798

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

02 Nov 2001

Group 1646

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CMA	*153	Gething and Sambrook, "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)
	*154	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells" <u>Proc. Natl. Acad. Sci. USA</u> 94(14):7509-7514 (Jul 8, 1997)
	*155	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)
	*156	Goeddel et al., "Direct Expression in Escherichia coli of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)
	*157	Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. coli" <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)
	*158	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
	*159	Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" <u>Proc. Natl. Acad. Sci. USA</u> 79:6777-6781 (November 1982)
	*160	Gough et al., "Molecular cloning of seven mouse immunoglobulin κ chain messenger ribonucleic acids" <u>Biochemistry</u> 19:2702-2710 (1980)
	*161	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
	*162	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)
	*163	Gray et al., "Expression of Human Immune Interferon cDNA in E. coli and Monkey Cells" <u>Nature</u> 295:503-508 (February 11, 1982)
	*164	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" <u>Gene</u> 18:355-360 (1982)
	*165	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
	*166	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
	*167	Handbook of Monoclonal Antibodies, Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
	*168	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York:Pergamon Press Vol. 7:149-167 (1968)
	*169	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)
	*170	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNFα)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
	*171	Holland and Holland, "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)
↓	*172	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)

Examiner

Eileen B-O'Hara

Date Considered

9/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Adams et al.		
		Filing Date 02 Nov 2001	Group 1646 To Be Assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
<p><i>CJA</i></p> <p>*173 Hoogenboom, "Designing and optimizing library selection strategies for generating high-affinity antibodies" <u>Trends in Biotechnology</u> 15(2):62-70 (Feb 1997)</p> <p>*174 Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)</p> <p>*175 Hsiao and Carbon, "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)</p> <p>*176 Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)</p> <p>*177 Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)</p> <p>*178 Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5" <u>Molecular Cell</u> 4(4):563-571 (1999)</p> <p>*179 Iliades et al., "Triabodies: single chain Fv fragments without a linker form trivalent trimers" <u>FEBS Letters</u> 409(3):437-441 (Jun 16, 1997)</p> <p>*180 Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)</p> <p>*181 Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" <u>Proc. Natl. Acad. Sci. USA</u> 90:2551-2555 (March 1993)</p> <p>*182 Jakobovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" <u>Nature</u> 362:255-258 (March 18, 1993)</p> <p>*183 Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)</p> <p>*184 Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i>" <u>Genetics</u> 85(1):23-33 (1977)</p> <p>*185 Jones, P.T. et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)</p> <p>*186 Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> (NIH Publ. No. 91-3242), 5th edition</p> <p>*187 Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)</p> <p>*188 Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region" <u>Gene</u> 7:141-152 (1979)</p> <p>*189 Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)</p> <p>*190 Kohler, G. and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)</p> <p>*191 Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)</p> <p>✓ *192 Koopman et al., "Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis" <u>Blood</u> 84:1415-1420 (1994)</p>				
Examiner <i>Cilar B. O'Hanrahan</i>		Date Considered 9/23/03		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		FEB 21 2001 PATENT & TRADEMARK OFFICE O I P E J C		
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
CJA	*193	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer" <u>Protein Engineering</u> 10(4):423-433 (Apr 1997)		
	*194	Kozak, "An analysis of vertebrate mRNA sequences: intimations of translational control" <u>Journal of Cell Biology</u> 115:887-903 (1991)		
	*195	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)		
	*196	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)		
	*197	Kyriakis et al., "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation" <u>Journal of Biological Chemistry</u> 271:24313-24316 (1996)		
	*198	Laimins et al., "Osmotic Control of kdp Operon Expression in Escherichia Coli" <u>Proc. Natl. Acad. Sci. USA</u> 78(1):464-468 (Jan 1981)		
	*199	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)		
	*200	Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P432) p. 115 (1991)		
	*201	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)		
	*202	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)		
	*203	LIFESEQ Database EST Sequence Reference "1"		
	*204	LIFESEQ Database EST Sequence Reference "2"		
	*205	Liu et al., "Dissection of TNF Receptor 1 Effector Functions: JNK Activation is not Linked to Apoptosis While NF- κ B Activation Prevents Cell Death" <u>Cell</u> 87:565-576 (1996)		
	*206	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)		
	*207	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)		
	*208	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" <u>Molecular & Cellular Biology</u> 3(6):1108-1122 (June 1983)		
	*209	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)		
	*210	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)		
	*211	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- α Activation" <u>J. Immunol.</u> 153:5274-5284 (1994)		
✓	*212	Maeda et al., "Production of Human α -interferon in Silkworm Using a Baculovirus Vector" <u>Nature</u> 315:592-594 (June 13, 1985)		
Examiner <i>Eileen B. O'Nara</i>		Date Considered 9/23/03		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT		Applicant Adams et al. Filing Date 02 Nov 2001 Group 1646 To Be Assigned		
(Use several sheets if necessary)				
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
CPA	*213	Mage et al., "Preparation of Fab and F(ab') ₂ Fragments from Monoclonal Antibodies" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pp. 79-97 (1987)		
	*214	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)		
	*215	<u>Mammalian Cell Biotechnology: A Practical Approach</u> , M. Butler, ed., IRL Press (1991)		
	*216	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)		
	*217	Mantel et al., "Rabbit β -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)		
	*218	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage." <u>J. Mol. Biol.</u> 222:581-597 (1991)		
	*219	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)		
	*220	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)		
	*221	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)		
	*222	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)		
	*223	Marsters et al., "Interferon γ Signals Via a High-Affinity Multisubunit Receptor Complex That Contains Two Types of Polypeptide Chain" <u>Proc. Natl. Acad. Sci. USA</u> 92:5401-5405 (1995)		
	*224	Martin et al., "Cell-free Reconstitution of Fas-, UV Radiation- and Ceramide-induced Apoptosis" <u>EMBO Journal</u> 14(21):5191-5200 (1995)		
	*225	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)		
	*226	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)		
	*227	Mather, J.P., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)		
	*228	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" <u>Methods in Enzymology</u> 65:499-560 (1980)		
	*229	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)		
	*230	Messing et al., "A System for Shotgun DNA Sequencing" <u>Nucleic Acids Research</u> 9(2):309-321 (1981)		
	*231	Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" <u>Genetic Engineering</u> , Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)		
✓	*232	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983)		
Examiner <i>Eileen B. O'Hanlon</i>		Date Considered <i>9/23/03</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				



FORM PTO-1449

 U.S. Dept. of Commerce
 Patent and Trademark Office

Atty Docket No.

P1101R2D1

Serial No.

10/052,798

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

02 Nov 2001

Group 1646

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

EA	*233	Mongkolsapaya et al., "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation" <u>Nature Structural Biology</u> 6(11):1048-1053 (Nov 1999)
	*234	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
	*235	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)
	*236	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)
	*237	Morrison et al., "Transfer and expression of immunoglobulin genes" <u>Annual Review of Immunology</u> 2:239-256 (1984)
	*238	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)
	*239	Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" <u>Science</u> 209:1422-1427 (Sep 1980)
	*240	Munro, "Uses of chimaeric antibodies" <u>Nature</u> 312:597 (1984)
	*241	Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)
	*242	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)
	*243	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
	*244	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
	*245	NCBI/GenBank EST; Locus AA223122: (computer printout attached)
	*246	NCBI/GenBank EST; Locus AA232440: (computer printout attached)
	*247	NCBI/GenBank EST; Locus HS75A7R: (computer printout attached)
	*248	Neri et al., "Engineering recombinant antibodies for immunotherapy" <u>Cell Biophysics</u> 27(1):47-61 (Aug 1995)
	*249	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)
	*250	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
	*251	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)
✓	*252	Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" <u>Molecular & Cellular Biology</u> 4(7):1293-1305 (July 1984)

Examiner

Elen B. O'Nara

Date Considered

9/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Adams et al.		
		Filing Date 02 Nov 2001	Group 1646 To Be Assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
GA	*253	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3 (6):547-553 (1990)		
	*254	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)		
	*255	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)		
	*256	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)		
	*257	Pavlakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" <u>Proc. Natl. Acad. Sci. USA</u> 78 (12):7398-7402 (December 1981)		
	*258	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)		
	*259	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)		
	*260	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P439) p. 118 (1991)		
	*261	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)		
	*262	Pluckthun, A., "Antibodies from Escherichia coli" <u>The Pharmacology of Monoclonal Antibodies</u> , Rosenberg and Moore, New York:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)		
	*263	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151 (5):2623-2632 (September 1, 1993)		
	*264	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)		
	*265	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)		
	*266	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)		
	*267	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" <u>Euro. Cytokine Network</u> (abstract No. 82) 7:210 (April-Jun 1996)		
	*268	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" <u>Programmed Cell Death Meeting</u> (abstract only) pps. 127 (20-24 September 1995)		
	*269	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 β Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)		
	*270	<u>Remington's Pharmaceutical Sciences</u> , Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)		
	*271	Reyes et al, "Expression of Human β -interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" <u>Nature</u> 297:598-601 (June 17, 1982)		
↓	*272	Rice and Baltimore, "Regulated expression of an immunoglobulin κ gene introduced into a mouse lymphoid cell line" <u>Proc. Natl. Acad. Sci. USA</u> 79:7862-7865 (1982)		
Examiner <i>Clier B. O'Kane</i>		Date Considered 9/23/03		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1101R2D1Serial No.
10/052, 798

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Adams et al.Filing Date
02 Nov 2001Group 1646
To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

EA	*273	Riechmann et al., "Reshaping human antibodies for therapy" <u>Nature</u> 332(24):323-327 (Mar 1988)
	*274	Rothe et al., "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor" <u>Cell</u> 78:681-692 (1994)
	*275	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)
	*276	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
	*277	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
	*278	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
	*279	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)
	*280	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)
	*281	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
	*282	Sharon et al., "Expression of a V _H C _K chimaeric protein in mouse myeloma cells" <u>Nature</u> 309:364-367 (1984)
	*283	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)
	*284	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
	*285	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity" <u>Journal of Immunology</u> 148(9):2918-2922 (1992)
	*286	Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" <u>Cell</u> 20:269-281 (June 1980)
	*287	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
	*288	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)
	*289	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" <u>Journal of Biological Chemistry</u> 266:14163-14166 (1991)
	*290	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
	*291	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)
✓	*292	Smith et al., "T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)


Examiner


Elin B. O'Nan

Date Considered

9/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT			Applicant Adams et al.	Filing Date 02 Nov 2001
(Use several sheets if necessary)				
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
  	*293	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" <u>Cell</u> 76:959-962 (1994)		
	*294	Soderlind et al., "Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems" <u>Immunological Reviews</u> 130:109-124 (Dec 1992)		
	*295	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry & Biophysics</u> 259(1):52-57 (1987)		
	*296	Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" <u>J. Molec. Appl. Genet.</u> 1:327-341 (1982)		
	*297	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)		
	*298	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)		
	*299	Stevenson et al., "A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared by Manipulations at the IgG Hinge" <u>Anti-Cancer Drug Design</u> 3(4):219-230 (1989)		
	*300	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)		
	*301	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)		
	*302	Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" <u>Molecular & Cellular Biology</u> 5:410-413 (1985)		
	*303	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)		
	*304	Suva et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" <u>Science</u> 237(4817):893-896 (Aug. 1987)		
*305	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)			
*306	Tartaglia et al., "A novel domain within the 55 kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)			
*307	Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)			
*308	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)			
*309	Tewari et al., "Yama/CPP32 β , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)			
*310	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)			
*311	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)			
*312	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)			
Examiner <i>Elisa B. O'Kane</i>		Date Considered <i>9/23/03</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101R2D1	Serial No. 10/052,798	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Adams et al.		
				Filing Date 02 Nov 2001	Group 1646 To Be Assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)						
 JA	*313	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)				
	*314	Tissue Culture, Kruse and Patterson, eds., New York: Academic Press (1973)				
	*315	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)				
	*316	Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" <u>Nature</u> 339:68-70 (1989)				
	*317	Tschumper and Carbon, "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)				
	*318	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)				
	*319	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)				
	*320	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)				
	*321	Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" <u>Bio/Technology</u> 8:135-139 (1990)				
	*322	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)				
	*323	Verhoeven, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)				
	*324	Verma et al., "Rel/NF- κ B/I κ B Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)				
	*325	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)				
	*326	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)				
	*327	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" <u>Nature</u> 356:314-317 (1992)				
	*328	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)				
	*329	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)				
	*330	Wells et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin" <u>Philos. Trans. Royal Soc. London Ser. A</u> 317:415-423 (1986)				
	*331	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)				
	*332	Winter et al., "Making antibodies by phage display technology" <u>Annual Review of Immunology</u> 12:433-455 (1994)				
	Examiner <i>Eric B. O'Hara</i>			Date Considered <i>9/23/03</i>		
	<small>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101R2D1	Serial No. 10/052,798
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Adams et al.	
				Filing Date 02 Nov 2001	Group 1646 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
 	*333	Wolff et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice" <u>Cancer Research</u> 53(11):2560-2565 (1993)			
	*334	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997)			
	*335	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (1997)			
	*336	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)			
	*337	Yaniv, M., "Enhancing Elements for Activation of Eukaryotic Promoters" <u>Nature</u> 297(6):17-18 (May 1982)			
	*338	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)			
	*339	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)			
	*340	Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987)			
	*341	Zoller and Smith, "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982)			
Examiner				Date Considered	9/23/03
<p><i>Elijah B. O'Hara</i></p> <p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					



Attachment
Off 9

Sheet 1 of 1

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101R2D1	Serial No. 10/052, 798
 LIST OF DISCLOSURES CITED BY APPLICANT		Applicant Adams et al.	
(Use several sheets if necessary)		Filing Date 02 Nov 2001	Group 1646 To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
EPA	1 6,417,328	09.07.02	Alnemri	1		JUL 2 9 2002
						TECH CENTER 1600/2000

JUL 29 2002

RECEIVED

Examiner	Elen B. O'Hara	Date Considered	9/22/03
----------	----------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

File Copy